PD2007

PD2007 is a selective dopamine transporter (DAT) inhibitor developed by P2D Bioscience as a first-in-class candidate for attention deficit hyperactivity disorder (ADHD) and obesity. It offers an improved safety profile over existing non-selective DAT inhibitors like Adderall and Concerta, with preclinical data indicating reduced body weight through increased energy expenditure rather than appetite suppression. The compound has received NIH grants for preclinical development, including studies toward an investigational new drug application, positioning it as a novel centrally acting agent with potential for oral administration.